Cover Image
市場調查報告書

生物學的治療藥的全球市場:2015年∼2019年

Global Biologic Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 317801
出版日期 內容資訊 英文 104 Pages
訂單完成後即時交付
價格
Back to Top
生物學的治療藥的全球市場:2015年∼2019年 Global Biologic Therapeutics Market 2015-2019
出版日期: 2015年10月21日 內容資訊: 英文 104 Pages
簡介

全球生物學的治療藥市場,預計2014年∼2019年以8.26%的年複合成長率成長。

本報告提供全球生物學的治療藥市場相關調查分析、市場規模與成長率、市場趨勢、市場的推動要素與課題、市場機會驗證、主要供應商等相關的系統性資訊。

第1章 摘要整理

  • 焦點

第2章 調查範圍

  • 市場概要
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點

第5章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 市場區隔:各分子類型

第7章 全球蛋白質治療藥市場

  • 簡介
  • 推動因素、課題、趨勢
  • 市場區隔:各分子類型

第8章 全球疫苗市場

  • 簡介
  • 推動因素、課題、趨勢
  • 市場區隔:各終端用戶年齡層

第9章 全球細胞療法市場

  • 簡介
  • 推動因素、課題、趨勢
  • 市場規模與預測

第10章 地理區分

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 推動市場要素

第12章 推動因素的影響

第13章 市場課題

第14章 推動因素與課題的影響

第15章 市場趨勢

第16章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第17章 主要供應商分析

  • Amgen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi

第18章 附錄

第19章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR7720

About biologic therapeutics

Biologic therapeutics include virus, therapeutic serums, toxins, allergenic products, antitoxin, blood components or derivatives, vaccines, blood, and proteins (except any chemically synthesized polypeptide). They also include analogous products, arsphenamine, or derivatives of arsphenamine (or any other trivalent organic arsenic compound) for the prevention, treatment, or cure of a disease. The differences between the biologics and small molecules include the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics have a higher molecular weight and a complex molecular structure. They are usually derived from living entities, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures (thermolabile) and light.

Technavio's analysts forecast the global biologic therapeutics market to grow at a CAGR of 8.26% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global biologic therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales protein therapeutics (monoclonal antibodies, enzymes, and other protein therapeutics).

Other protein therapeutics covers proteins such as cytokines, fusion proteins, peptide antibiotics, peptide hormones, and blood factors.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Technavio's report, Global Biologic Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global biologic therapeutics market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Amgen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi

Other Prominent Vendors

  • AbbVie
  • AstraZeneca
  • Bavarian Nordic
  • Baxter International
  • Beijing Minhai Biotechnology
  • Bharat Biotech
  • Bharat Immunologicals and Biologicals
  • Bio Med Pvt.
  • bioCSL
  • Biodel
  • Bristol-Myers Squibb
  • Diamyd Medical
  • DiaVacs
  • Dynavax Technologies
  • Eli Lilly
  • Generex Biotechnology
  • Hualan Biological Engineering
  • Imunoloski Zavod
  • Indian Immunologicals
  • Janssen
  • JN International Medical
  • Kaketsuken
  • LG Life Sciences
  • Macrogenics
  • MannKind
  • Merck
  • Mitsubishi Tanabe Pharma
  • Nuron Biotech
  • Osiris Therapeutics
  • Pfizer
  • Protalix
  • Protein Sciences
  • Serum Institute of India
  • Shenzhen Kangtai Biological Products
  • Sinovac Biotech
  • Tolerion
  • Vacunas Finlay
  • XOMA
  • Zydus Cadila

Market driver

  • Reimbursement support for biologics
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Emergence of targeted and combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by type of molecules

PART 07: Global protein therapeutics market

  • Introduction
  • Drivers, challenges, and trends
  • Market segmentation by type of molecules

PART 08: Global vaccines market

  • Introduction
  • Drivers, challenges, and trends
  • Market segmentation by end-user age group

PART 09: Global cell therapy market

  • Introduction
  • Drivers, challenges, and trends
  • Market size and forecast

PART 10: Geographical segmentation

  • Biologic therapeutics market in Americas
  • Biologic therapeutics market in EMEA
  • Biologic therapeutics market in APAC

PART 11: Market drivers

  • Reimbursement support for biologics
  • Promising drug pipeline
  • Focus on development of novel mechanisms
  • Increase in industry-academia collaborations

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Stringent regulatory guidelines
  • Fierce market competition
  • Cold chain management
  • Poor diagnosis and screening

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Emergence of targeted and combination therapies
  • Increase in R&D
  • Shift in focus to untapped markets
  • Rise in public awareness

PART 16: Vendor landscape

  • Competitive scenario
  • Key news
  • Mergers and acquisitions
  • Market share analysis
  • Amgen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi
  • Other and future prominent vendors

PART 17: Key vendor analysis

  • Amgen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global biologic therapeutics market 2014-2019 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Global biologic therapeutics market segmentation by type of molecules
  • Exhibit 05: Global biologic therapeutics market segmentation by type of molecules 2014
  • Exhibit 06: Global biologic therapeutics market segmentation by type of molecules 2014-2019 ($ billions)
  • Exhibit 07: Key drivers and challenges of global protein therapeutics market
  • Exhibit 08: Key trends of global protein therapeutics market
  • Exhibit 09: Global protein therapeutics market 2014-2019 ($ billions)
  • Exhibit 10: Global protein therapeutics market 2014
  • Exhibit 11: Global protein therapeutics market by type of molecules 2014-2019 ($ billions)
  • Exhibit 12: Global monoclonal antibodies market 2014-2019 ($ billions)
  • Exhibit 13: Global enzymes market 2014-2019 ($ billions)
  • Exhibit 14: Global other protein therapeutics market 2014-2019 ($ billions)
  • Exhibit 15: Drivers of global vaccines market
  • Exhibit 16: Challenges of global vaccines market
  • Exhibit 17: Trends in global vaccines market
  • Exhibit 18: Global vaccines market 2014-2019 ($ billions)
  • Exhibit 19: Global vaccines market by end-user age group 2014
  • Exhibit 20: Global vaccines market by end-user age group 2014-2019 ($ billions)
  • Exhibit 21: Global pediatric vaccines market 2014-2019 ($ billions)
  • Exhibit 22: Global adult vaccines market 2014-2019 ($ billions)
  • Exhibit 23: Key factors influencing the global cell therapy market
  • Exhibit 24: Global cell therapy market 2014-2019 ($ billions)
  • Exhibit 25: Global biologic therapeutics market by geography 2014
  • Exhibit 26: Biologic therapeutics market in Americas 2014-2019 ($ billions)
  • Exhibit 27: Biologic therapeutics market in EMEA 2014-2019 ($ billions)
  • Exhibit 28: Biologic therapeutics market in APAC 2014-2019 ($ billions)
  • Exhibit 29: Global biologic therapeutics market by geography 2014-2019 ($ billions)
  • Exhibit 30: Impact of drivers
  • Exhibit 31: Impact of drivers and challenges
  • Exhibit 32: Revenue of Enbrel 2012-2014 ($ millions)
  • Exhibit 33: Revenue of Epogen 2012-2014 ($ millions)
  • Exhibit 34: Revenue of Neulasta/Neupogen 2012-2014 ($ millions)
  • Exhibit 35: Revenue of vectibix 2012-2014 ($ millions)
  • Exhibit 36: Revenue of Xgeva 2012-2014 ($ millions)
  • Exhibit 37: Revenue of Prolia 2012-2014 ($ millions)
  • Exhibit 38: Revenue of Avastin 2012-2014 ($ millions)
  • Exhibit 39: Revenue of Kadcyla 2013 and 2014 ($ millions)
  • Exhibit 40: Revenue of Lucentis 2012-2014 ($ millions)
  • Exhibit 41: Revenue of Rituxan/MabThera 2012-2014 ($ millions)
  • Exhibit 42: Revenue of Pegasys 2012-2014 ($ millions)
  • Exhibit 43: Revenue of Perjeta 2013 and 2014 ($ millions)
  • Exhibit 44: Revenue of Pulmozyme 2012-2014 ($ millions)
  • Exhibit 45: Revenue of Pulmozyme 2012-2014 ($ millions)
  • Exhibit 46: Revenue of Apridra 2012-2014 ($ millions)
  • Exhibit 47: Revenue of Cerezyme 2012-2014 ($ millions)
  • Exhibit 48: Revenue of Fabrazyme 2012-2014 ($ millions)
  • Exhibit 49: Revenue of Myozyme/Lumizyme 2012-2014 ($ millions)
  • Exhibit 50: Revenue of Lantus 2012-2014 ($ millions)
  • Exhibit 51: Revenue of Zaltrap 2012-2014 ($ millions)
  • Exhibit 52: Amgen: Business segmentation by revenue 2014
  • Exhibit 53: Amgen: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 54: Amgen: Geographical segmentation by revenue 2014
  • Exhibit 55: Novo Nordisk: Business segmentation by revenue 2014
  • Exhibit 56: Novo Nordisk: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 57: Novo Nordisk: Geographical segmentation by revenue 2014
  • Exhibit 58: Novo Nordisk: R&D expenditure 2014
  • Exhibit 59: Business segmentation by revenue 2013 and 2014 ($ billions)
Back to Top